Literature DB >> 9081563

Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs.

I Creese, D R Burt, S H Snyder.   

Abstract

Tritiated haloperidol and tritiated dopamine label postsynaptic dopamine receptors in mammalian brain. Clinical potencies of butyrophenones, phenothiazines, and related drugs correlate closely with their ability to inhibit tritiated haloperidol binding. These binding methods provide a simple in vitro means for evaluating new drugs as potential antischizophrenic agents.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 9081563     DOI： 10.1176/jnp.8.2.223

Source DB:  PubMed          Journal:  J Neuropsychiatry Clin Neurosci        ISSN： 0895-0172            Impact factor:   2.198


  10 in total

Review 1.  Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection.

Authors:  Jeffrey A Lieberman; Frank P Bymaster; Herbert Y Meltzer; Ariel Y Deutch; Gary E Duncan; Christine E Marx; June R Aprille; Donard S Dwyer; Xin-Min Li; Sahebarao P Mahadik; Ronald S Duman; Joseph H Porter; Josephine S Modica-Napolitano; Samuel S Newton; John G Csernansky
Journal:  Pharmacol Rev       Date:  2008-09       Impact factor: 25.468

Review 2.  Potential synergistic action of 19 schizophrenia risk genes in the thalamus.

Authors:  Edwin A Richard; Elizaveta Khlestova; Roshan Nanu; John E Lisman
Journal:  Schizophr Res       Date:  2016-09-16       Impact factor: 4.939

3.  K+ channel modulation in rodent neurohypophysial nerve terminals by sigma receptors and not by dopamine receptors.

Authors:  R A Wilke; P J Lupardus; D K Grandy; M Rubinstein; M J Low; M B Jackson
Journal:  J Physiol       Date:  1999-06-01       Impact factor: 5.182

4.  Immunochemical localization of vesicular monoamine transporter 2 (VMAT2) in mouse brain.

Authors:  Rachel A Cliburn; Amy R Dunn; Kristen A Stout; Carlie A Hoffman; Kelly M Lohr; Alison I Bernstein; Emily J Winokur; James Burkett; Yvonne Schmitz; William M Caudle; Gary W Miller
Journal:  J Chem Neuroanat       Date:  2016-11-09       Impact factor: 3.052

5.  Modeling and protein engineering studies of active and inactive states of human dopamine D2 receptor (D2R) and investigation of drug/receptor interactions.

Authors:  Ramin Ekhteiari Salmas; Mine Yurtsever; Matthias Stein; Serdar Durdagi
Journal:  Mol Divers       Date:  2015-02-05       Impact factor: 2.943

Review 6.  The mediodorsal thalamic nucleus and schizophrenia.

Authors:  Raúl Alelú-Paz; José Manuel Giménez-Amaya
Journal:  J Psychiatry Neurosci       Date:  2008-11       Impact factor: 6.186

7.  The dopaminergic stabilizer pridopidine increases neuronal activity of pyramidal neurons in the prefrontal cortex.

Authors:  Benjamin Gronier; Susanna Waters; Henrik Ponten
Journal:  J Neural Transm (Vienna)       Date:  2013-03-07       Impact factor: 3.575

8.  Seropositivity and serointensity of Toxoplasma gondii antibodies and DNA among patients with schizophrenia.

Authors:  Ainsah Omar; Osman Che Bakar; Nor Fatini Adam; Hakim Osman; Arina Osman; Ahmad Hatim Suleiman; Mohd Rizal Abdul Manaf; Mohd Ikhsan Selamat
Journal:  Korean J Parasitol       Date:  2015-02-27       Impact factor: 1.341

9.  Haloperidol Abrogates Matrix Metalloproteinase-9 Expression by Inhibition of NF-κB Activation in Stimulated Human Monocytic Cells.

Authors:  Yueh-Lun Lee; Che-Jen Hsiao; Fan-Li Lin; Jing-Shiun Jan; Yung-Chen Chou; Yen-Yu Lin; Chih-Kuang Chen; Kwok-Keung Lam; George Hsiao
Journal:  Mediators Inflamm       Date:  2018-04-12       Impact factor: 4.711

10.  Targeting Aquaporin-4 Subcellular Localization to Treat Central Nervous System Edema.

Authors:  Philip Kitchen; Mootaz M Salman; Andrea M Halsey; Charlotte Clarke-Bland; Justin A MacDonald; Hiroaki Ishida; Hans J Vogel; Sharif Almutiri; Ann Logan; Stefan Kreida; Tamim Al-Jubair; Julie Winkel Missel; Pontus Gourdon; Susanna Törnroth-Horsefield; Matthew T Conner; Zubair Ahmed; Alex C Conner; Roslyn M Bill
Journal:  Cell       Date:  2020-05-14       Impact factor: 41.582
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.